Back to Search
FABIO FIORE, MD
MD
Orthopaedic Surgery Physician
NPI: 1720042609Individual
Specialties, Licenses & Credentials
Orthopaedic Surgery PhysicianPrimary
Orthopaedic Surgery
Code: 207X00000X
ME0056708(FL)
CMS Specialties
PrimaryORTHOPEDIC SURGERY
Education
OTHER
Class of 1980
Research & Publications (20)
Rectal villous tumours: MR features and correlation with TRUS in the preoperative evaluation.
PMID 19157738·Eur J Radiol·2010
4-observational
Inhibitors of the hepatitis C virus NS3 protease with basic amine functionality at the P3-amino acid N-terminus: discovery and optimization of a new series of P2-P4 macrocycles.
PMID 19624135·J Med Chem·2009
7-preclinical
Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
PMID 19493593·Eur J Med Chem·2009
7-preclinical
Synthesis and evaluation of novel phosphoramidate prodrugs of 2'-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase.
PMID 19181520·Bioorg Med Chem Lett·2009
4-observational
Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate.
PMID 19569735·Xenobiotica·2009
7-preclinical
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method.
PMID 19463773·Exp Hematol·2009
4-observational
N-(4-Fluorobenzyl)-3-hydroxy-9,9-dimethyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrazino[1,2-a]pyrimidine-2-carboxamides a novel class of potent HIV-1 integrase inhibitors.
PMID 19523819·Bioorg Med Chem Lett·2009
7-preclinical
Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
PMID 19441846·J Med Chem·2009
7-preclinical
Optimization of thienopyrrole-based finger-loop inhibitors of the hepatitis C virus NS5B polymerase.
PMID 19672916·ChemMedChem·2009
7-preclinical
The metamorphosis of supernova SN 2008D/XRF 080109: a link between supernovae and GRBs/hypernovae.
PMID 18653846·Science·2008
8-other
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
PMID 18763751·J Med Chem·2008
8-other
Broadband observations of the naked-eye gamma-ray burst GRB 080319B.
PMID 18784718·Nature·2008
8-other
Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
PMID 18809328·Bioorg Med Chem Lett·2008
7-preclinical
Development of 2-t butyl-N-methyl pyrimidones as potent inhibitors of HIV integrase.
PMID 18362069·Bioorg Med Chem Lett·2008
7-preclinical
A tension-free technique for the repair of large incisional hernias during abdominal surgery: results and long-term outcome.
PMID 19051954·S Afr J Surg·2008
8-other
Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors.
PMID 18217703·J Med Chem·2008
7-preclinical
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase.
PMID 17170728·Leukemia·2007
8-other
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
PMID 17403919·Blood·2007
3-trial
Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-NMR spectroscopy.
PMID 17896326·Xenobiotica·2007
7-preclinical
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
PMID 17987788·J Exp Clin Cancer Res·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 803 S PARSONS AVE
BRANDON, FL 33511 - Phone
- (813) 651-9888
Quick Facts
- NPI
- 1720042609
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile